Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Short Interest Update

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 9,599 shares, a growth of 86.7% from the November 30th total of 5,141 shares. Currently, 0.9% of the shares of the company are short sold. Based on an average daily trading volume, of 8,344 shares, the days-to-cover ratio is presently 1.2 days. Based on an average daily trading volume, of 8,344 shares, the days-to-cover ratio is presently 1.2 days. Currently, 0.9% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Addex Therapeutics in a research report on Tuesday, October 14th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Addex Therapeutics Price Performance

NASDAQ:ADXN opened at $7.99 on Monday. Addex Therapeutics has a one year low of $6.51 and a one year high of $12.05. The business has a fifty day moving average price of $8.44 and a 200-day moving average price of $8.60. The firm has a market capitalization of $9.83 million, a price-to-earnings ratio of -1.88 and a beta of 1.57.

Addex Therapeutics (NASDAQ:ADXN) last released its quarterly earnings results on Thursday, December 4th. The company reported ($1.51) earnings per share (EPS) for the quarter. The company had revenue of $0.04 million for the quarter. Addex Therapeutics had a net margin of 3,584.49% and a negative return on equity of 80.69%.

Addex Therapeutics Company Profile

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.